Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds

Launched by ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · Apr 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a topical solution called 0.5% timolol can help heal wounds faster in patients who have undergone a specific type of skin surgery called Mohs Micrographic Surgery (MMS). This surgery is often used to treat skin cancer, and sometimes the wounds created cannot be stitched closed and are left to heal naturally. The researchers want to find out if applying timolol to these wounds can speed up healing and improve the appearance of the scars compared to standard care.

To participate in this trial, individuals must be at least 18 years old, scheduled for MMS at a specific location, and have an open surgical wound between 0.5 cm and 4 cm. They also need to speak English and agree to follow the study procedures. However, some people may not be eligible, such as those under 18, pregnant or breastfeeding women, and those taking certain medications. Participants in the trial will be monitored for their healing progress and any side effects that may occur. This study aims to provide more information about the benefits of timolol for wound healing in surgical patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Be scheduled to undergo MMS at 234 East 85th St for a skin cancer that is deemed Mohs
• • Appropriate by the Mohs surgery appropriate use criteria
• • Have an open surgical wound \< 4 cm and \> 0.5 cm
• • Be ≥18 years of age
• • English-speaking
• • Provide a signed and dated informed consent form
• • State willingness to comply with all study procedures
• Exclusion Criteria:
• • Age less than 18 years of age
• • Open surgical wound \> 4 cm
• • If tumor clearance cannot be achieved with MMS
• • Pregnant women
• • Breastfeeding women
• • Patients who are taking oral beta-blockers (ie oral timolol, metoprolol, carvedilol, propranolol, atenolol)
• • Patients who are currently taking any of the following medications: clonidine, digoxin, methyldopa, quinidine, fluoxetine and paroxetine, bupropion
• • Patient currently taking a calcium channel blocker AND has pre-existing heart failure as defined by a reduced ejection fraction
• • Patients with pre-existing hypotension
• • Pre-existing diagnosis of sinus bradycardia
• • Pre-existing diagnosis of second or third degree atrioventricular block
• • Congestive heart failure
• • Pre-existing diagnosis of severe asthma
• • Pre-existing diagnosis of chronic obstructive pulmonary disease
• • Any known hypersensitivity to 0.5% timolol solution
• • Patients who have a wound where primary closure is feasible and desired by the patient
• • Defect size \<0.5 cm
• • Prior sensitivity or known allergy to timolol